Abstract
We present a case of acute myeloblastic leukemia (AML-M2) with a complex t(8;21) translocation and additional acquired chromosomes yielding a hyperdiploid karyotype. AML1/ETO transcript was observed by reverse transcription-polymerase chain reaction. Fluorescence in situ hybridization (FISH), spectral karyotyping (SKY), and comparative genomic hybridization (CGH) were performed to further identify the chromosomes observed by G banding. The patient was treated according to our current protocol for AML. He remains in complete remission +11 months from diagnosis. Further follow-up of this patient and the analysis of a larger number of children are needed to define whether the gains of the specific extra chromosomes modify the good prognosis that t(8;21) confers to this subgroup of AML.
(c) 2007 Wiley-Liss, Inc.
Publication types
-
Case Reports
-
Comparative Study
MeSH terms
-
Aneuploidy*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Chromosomes, Human, Pair 21 / genetics
-
Chromosomes, Human, Pair 21 / ultrastructure*
-
Chromosomes, Human, Pair 8 / genetics
-
Chromosomes, Human, Pair 8 / ultrastructure*
-
Core Binding Factor Alpha 2 Subunit / genetics*
-
Cytarabine / administration & dosage
-
Cytogenetic Analysis
-
Etoposide / administration & dosage
-
Humans
-
Idarubicin / administration & dosage
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / genetics*
-
Male
-
Nucleic Acid Hybridization
-
Oncogene Proteins, Fusion / genetics*
-
Polymerase Chain Reaction
-
RUNX1 Translocation Partner 1 Protein
-
Translocation, Genetic*
Substances
-
AML1-ETO fusion protein, human
-
Core Binding Factor Alpha 2 Subunit
-
Oncogene Proteins, Fusion
-
RUNX1 Translocation Partner 1 Protein
-
Cytarabine
-
Etoposide
-
Idarubicin